AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG Initiate First-Ever Clinical Trial of Microarray Patches for Psoriasis Treatment

March 19, 2019

ANDERNACH, Germany & BALLERUP, Denmark--(BUSINESS WIRE)--Mar 19, 2019--LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005358/en/

A microarray patch (also known as a microneedle patch) is a polymeric, microscopic array which delivers encapsulated drugs by perforating the outer stratum corneum with numerous microneedles. The needles are biodegradable and will dissolve as they release the drug in the skin.

This is the first time that microarray patch technology is applied to psoriasis treatment, representing a novel dosage form with several potential benefits for patients: The microarray patch enables slow release of the drug (betamethasone and calcipotriol), which means that treatment frequency can potentially be reduced from one or more times daily to once weekly. Furthermore the patch may reduce or potentially eliminate the need for application of topicals such as ointments. Application of the patch is precise due to the small size of the micro needles ensuring that only affected skin is treated.

The micro array patch for psoriasis treatment has been developed jointly between LEO Pharma and LTS’ laboratories and has Good Manufacturing Practice (GMP) status. The project is the first result of a partnership agreement which the two companies entered in 2016.

“After a successful preclinical development in the last two years, initiating a human study in corporation with LEO Pharma is the next major milestone. Our Micro Array Patch (MAP) platform allows the active ingredient to be released directly into the skin MAP innovation is driven by a productive and constructive cooperation using core competences of LEO Pharma and LTS,” said Stefan Henke, Head of LTS‘s Innovative Injection Systems Unit.

- Full release attached -

View source version on businesswire.com:https://www.businesswire.com/news/home/20190319005358/en/

CONTACT: For further information, please contact:LTS Lohmann Therapie-Systems AG

Dr. Iris Schnitzler, Marketing and Market Services,

iris.schnitzler@ltslohmann.deLEO Pharma A/S

Trine Juul Wengel, Global External Communications

tewdk@leo-pharma.com

Tel.: +45 20732037

KEYWORD: EUROPE DENMARK GERMANY

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE PHYSICAL THERAPY

SOURCE: LEO Pharma

Copyright Business Wire 2019.

PUB: 03/19/2019 05:30 AM/DISC: 03/19/2019 05:30 AM

http://www.businesswire.com/news/home/20190319005358/en